Intelligent Bio Solutions starts interference study for FDA clearance of codeine fingerprint drug test system

Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc.

INBS

0.00
  • Intelligent Bio Solutions launched an Interference Study to support an FDA 510(k) filing for U.S. clearance of its fingerprint-based codeine screening system.
  • Results have not been presented; the study is expected to finish by mid-July 2026 for inclusion in a future 510(k) submission.
  • The trial aims to show the device remains reliable when users have handled common substances that could trigger misleading test outcomes.
  • The program enrolls 75 healthy adults, running alongside a Method Comparison Study as part of a broader package supporting a planned U.S. market entry.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intelligent Bio Solutions Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606160830PRIMZONEFULLFEED9747557) on June 16, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.